or Try an Advanced Search...

    Technical Analysis for GUTS - Fractyl Health, Inc.

    Grade Last Price % Change Price Change
    F 6.70 -0.30% -0.02
    GUTS closed down 0.3 percent on Friday, April 26, 2024, on 32 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong N/A Down Up
    Historical GUTS trend table...
    Date Alert Name Type % Chg
    Doji - Bearish? Reversal 0.00%
    MACD Bullish Signal Line Cross Bullish -0.30%
    Lower Bollinger Band Walk Weakness -0.30%
    Lower Bollinger Band Touch Weakness -0.30%
    Oversold Stochastic Weakness -0.30%
    Outside Day Range Expansion 6.52%
    Gapped Up Strength 6.52%
    Lower Bollinger Band Touch Weakness 6.52%
    Oversold Stochastic Weakness 6.52%
    Narrow Range Bar Range Contraction 2.29%
    Older End-of-Day Signals for GUTS ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 16 hours ago
    10 DMA Support about 17 hours ago
    60 Minute Opening Range Breakout about 17 hours ago
    Rose Above Previous Day's High about 17 hours ago
    Down 3% about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GUTS Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Fractyl Health, Inc. Description

    Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Diabetes Gene Therapy Obesity

    Is GUTS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 The 3 Most Volatile Stocks for Short-Term Traders: April 2024
    Apr 3 Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Apr 2 Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 2 Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
    Apr 2 PVH Posts Q4 Results, Joins Humana, CVS Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Apr 1 Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
    Apr 1 Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Apr 1 Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
    Mar 19 Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March
    Mar 12 UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
    See more GUTS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.5
    52 Week Low 5.7501
    Average Volume 349,207
    200-Day Moving Average 0.00
    50-Day Moving Average 7.55
    20-Day Moving Average 6.89
    10-Day Moving Average 6.60
    Average True Range 0.64
    RSI (14) 42.53
    ADX 33.44
    +DI 11.75
    -DI 22.53
    Chandelier Exit (Long, 3 ATRs) 6.06
    Chandelier Exit (Short, 3 ATRs) 7.68
    Upper Bollinger Bands 7.68
    Lower Bollinger Band 6.10
    Percent B (%b) 0.38
    BandWidth 22.93
    MACD Line -0.30
    MACD Signal Line -0.33
    MACD Histogram 0.0291
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.26
    Resistance 3 (R3) 7.25 7.05 7.17
    Resistance 2 (R2) 7.05 6.90 7.05 7.14
    Resistance 1 (R1) 6.87 6.81 6.96 6.89 7.11
    Pivot Point 6.67 6.67 6.72 6.68 6.67
    Support 1 (S1) 6.50 6.53 6.59 6.51 6.29
    Support 2 (S2) 6.30 6.44 6.30 6.26
    Support 3 (S3) 6.12 6.30 6.23
    Support 4 (S4) 6.14